PeptideStack
5.2kquestions
20kanswers
220users

Is a sampling plan from ERP sufficient basis to skip independent testing?

Asked 2 Nov 2024Modified 21 months agoViewed 18k times
37

Setup, so nobody has to ask: sampling plan · ERP.

This is a planning question. I know what my options are; I do not know how to weigh them.

What I want is the minimum viable version, which I suspect is smaller than what I would design.

What does a sensible plan look like, and what are the decision points?

coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

771 questionsbatch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

910 questionsharm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
shareeditfollowflag
OB
askedone_ml_bac18k272 Nov 2024

No answers yet

This question has not been answered. It has been viewed 18k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.